165 results match your criteria: "Royal Cancer Hospital[Affiliation]"
Environ Health Perspect
May 1996
Section of Molecular Carcinogenesis, Royal Cancer Hospital, Sutton, Surrey, United Kingdom.
The causes of much of human cancer remain obscure. The fraction that is spontaneous is unknown and cannot be calculated until all known external causes have been accounted for. This is not a feasible proposition.
View Article and Find Full Text PDFJ Epidemiol Community Health
April 1996
Chester Beatty Research Institute, Royal Cancer Hospital, London.
A history of cohort analysis has been given, and it has been pointed out that the bulk of the literature on the subject has dealt with concepts that assume either that graduation and possibly extrapolation are desirable, preferably in conformity with some formula expressing what is implicitly accepted as a "law of mortality", or that, whether or not a fixed pattern of mortality exists, the intensity of mortality risk is largely determined in early life. The view is advanced that either concept alone, is, or both concepts together are, inadequate and may lead to an improper assessment of the nature-nurture complex, since environment and therapeutic measures are constantly changing. The plea is made for the technique of cohort analysis to be used as a narrative or historical technique, and for a synthesis of knowledge derived from social history, medical history, and cohort analysis to be made to interpret the narrative.
View Article and Find Full Text PDFCarcinogenesis
April 1996
Section of Molecular Carcinogenesis, Royal Cancer Hospital, Sutton, Surrey, UK.
In patients with familial adenomatous polyposis (FAP), duodenal adenomas cluster around the ampulla and their distribution closely resembles mucosal exposure to bile, suggesting a role for bile in their development. Previous studies using 32P-postlabeling to detect DNA adducts, have provided evidence to support this hypothesis. We have now investigated the role of metabolic activation in influencing the levels and patterns of adduct formation by incubating precolectomy gallbladder bile from FAP patients and bile from unaffected controls with human lymphoblastoid cell lines that are metabolically proficient (MCL-5), or deficient (CCRF).
View Article and Find Full Text PDFCancer Treat Res
January 1997
Cancer Screening Evaluation Unit, Institute of Cancer Research, Royal Cancer Hospital, Sutton, Surry, United Kingdom.
Cancer Chemother Pharmacol
May 1996
Cancer Research Campaign Centre For Cancer Therapeutics, Institute of Cancer Research, Royal Cancer Hospital, Sutton, UK.
We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.
View Article and Find Full Text PDFMol Immunol
July 1995
Section of Immunology, Royal Cancer Hospital, Sutton, Surrey, UK.
Eight syngeneic rat monoclonal antibodies that recognize structurally overlapping epitopes on the chondroitin proteoglycan NG2, a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN, have been analysed for the sequence of their immunoglobulin heavy (H) and light (L) chain variable (V) regions. This analysis defined five groups of antibodies which are very similar for both the H and L chains and revealed that a wide range of different V regions are capable of binding to the same antigenic determinant. However, three mAbs, 11/160, ALN/12/17 and ALN/9/94, which recognize a sequential epitope, were found to use almost identical heavy (V-D-J) and light (V-J) chains in regions demonstrating an exclusivity in specific protein-protein interaction for this particular epitope.
View Article and Find Full Text PDFGut
June 1995
Section of Molecular Carcinogenesis, Haddow Laboratories, Royal Cancer Hospital, Sutton, Surrey.
Patients with familial adenomatous polyposis (FAP) develop periampullary duodenal tumours, suggesting that bile contributes to their formation. The hypothesis that bile contains carcinogens has been tested by looking for DNA adducts (markers of carcinogen exposure) in the duodenum of patients with or without FAP and by determining whether bile can produce DNA adducts in vitro. Using 32P-postlabelling to detect adducts, there was an excess (compared with unaffected patients) of DNA adducts in the duodenum of FAP patients and an excess of DNA adducts in the small bowel of rats treated with FAP bile, while bile from FAP patients formed significantly more DNA adducts in vitro than did bile from controls.
View Article and Find Full Text PDFCarcinogenesis
May 1995
Section of Molecular Carcinogenesis, Haddow Laboratories, Royal Cancer Hospital, Sutton, Surrey, UK.
Much of bladder cancer in East Africa and the Middle East is attributed to chronic urinary infection with Schistosoma haematobium ('schistosomiasis'). Most schistosomal bladder cancer (SBC) is squamous cell carcinoma (SCC) and occurs in the fifth decade of life. In contrast, nonschistosomal bladder cancer (NSBC) in Western countries usually occurs in the seventh decade of life and is largely transitional cell carcinoma (TCC).
View Article and Find Full Text PDFClin Chem
July 1994
Section of Molecular Carcinogenesis, Haddow Laboratories, Royal Cancer Hospital, Sutton, Surrey, UK.
The population can be divided into four groups, or "oncodemes," depending on the relative contributions of environment and genetics to their risk of cancer. These oncodemes are: 1) background (random mutations in normal people); 2) environmental (environmental carcinogens acting on normal people); 3) environmental/genetic (environmental carcinogens acting on genetic susceptibility); and 4) genetic, with genetic susceptibility being more important than environmental exposure. Most cancer probably occurs in oncodemes 2 and 3.
View Article and Find Full Text PDFExp Cell Res
April 1994
Section of Drug Development, Institute of Cancer Research: Royal Cancer Hospital, Sutton, United Kingdom.
After treatment of the human ovarian carcinoma cell line, CH1, with cisplatin, cells detached from the culture dish in a time- and dose-dependent fashion. These cells showed morphological changes indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments, but the DNA had been cut into larger fragments (30 kbp) of a size associated with chromatin loops.
View Article and Find Full Text PDFBr J Cancer
January 1994
Section of Drug Development, Institute of Cancer Research, Royal Cancer Hospital, Sutton, UK.
Cell killing of L1210 cells by cisplatin has been studied using flow cytometry and DNA gel electrophoresis. Ten hours after a supralethal dose of drug (100 microM), extensive apoptosis was induced. Cells were also susceptible to the induction of apoptosis by nutritional deprivation, for example by incubation in arginine-deficient medium.
View Article and Find Full Text PDFJpn J Cancer Res
March 1993
Institute of Cancer Research Royal Cancer Hospital, Chester Beatty Laboratories, London, United Kingdom.
Eur J Nucl Med
February 1993
Department of Physics, Royal Cancer Hospital, Sutton, Surrey, UK.
Radiolabelled amino acids combined with positron emission tomography (PET) show promise for the accurate delineation of viable tumour extent and may also provide a rapid and sensitive indicator of response to therapy. We have investigated the potential use of the radioiodinated amino acid analogue L-3-iodo-alpha-methyl tyrosine (IMT) for these purposes using experimental tumours in hooded rats. Preliminary studies using HSN tumours and IMT labelled with iodine-125 demonstrated maximum tumour uptake at 15 min post injection although an improved tumour-to-brain ratio was seen at 24 h due to the relatively poor retention of IMT in normal brain.
View Article and Find Full Text PDFJ Cell Sci
November 1991
Institute of Cancer Research, Royal Cancer Hospital, Haddow Laboratories, Sutton, Surrey, UK.
Differentially expressed membrane antigens have been used to flow-sort viable luminal epithelial and myoepithelial cells from freshly disaggregated adult virgin rat mammary parenchyma. Resulting cultures and clones have been characterized morphologically and by a panel of antibodies that recognise cell-type-specific cytoskeletal antigens in the intact mammary gland. Five clonal phenotypes were recognisable by morphological criteria, three (types 1-3) exclusively associated with sorted luminal epithelial (25.
View Article and Find Full Text PDFBr J Cancer
July 1991
Institute of Cancer Research, Royal Cancer Hospital, Sutton, Surrey, UK.
The vascularity of 107 primary cutaneous melanomas has been characterized by morphometric histological analysis. The lesions selected for study were of thickness 0.85-1.
View Article and Find Full Text PDFMol Immunol
June 1991
Section of Immunology, Royal Cancer Hospital, Surrey, U.K.
The isolation and characterization of an isotype-specific autoantibody-secreting hybridoma NET/2/3 from rats bearing the syngeneic tumour HSN is described. This rheumatoid factor of the IgM class recognizes an epitope within the hinge region of rat immunoglobulins of the IgG2b subclass which is destroyed by reduction of disulphide bonds. The specificity of NET/2/3, although not allotype-restricted, is highly isotype-restricted, as it does not bind to rat Ig other than IgG2b, nor does it react with the majority of mouse IgG, although some reactivity occurs with mouse IgG3.
View Article and Find Full Text PDFJ Immunol
April 1991
Institute of Cancer Research, Royal Cancer Hospital, Belmont, Sutton, Surrey, UK.
Twelve syngeneic anti-idiotopic mAb (anti-idiotypic/idiotopic antibodies Ab2)) were prepared from CBH/Cbi rats immunized with one of three monoclonal anti-HSN antibodies (Ab1) (11/160, ALN/11/53, or ALN/16/53) specific for the HSN tumor. The sera of the rats used for hybridoma production and all of the monoclonal Ab2 specifically inhibited the binding to HSN of the immunizing Ab1 only. It is concluded that, in this completely syngeneic system, only the private idiotopes associated with the antibody-combining site were immunogenic.
View Article and Find Full Text PDFDifferentiation
April 1991
Royal Cancer Hospital, Haddow Laboratories, Sutton, Surrey, UK.
Luminal and myoepithelial cells have been separated from normal adult human breast epithelium using fluorescence activated cell sorting. Their isolation was based on the exclusive expression of two surface antigens, epithelial membrane antigen (EMA) and the common acute lymphoblastic leukaemia antigen (CALLA/CD10/neutral endopeptidase 24.11).
View Article and Find Full Text PDFInt J Cancer
February 1991
Institute of Cancer Research, Royal Cancer Hospital, Sutton, Surrey, UK.
Polypeptides containing the tumour antigenic determinant present on the external domain of a membrane antigen of the 3-4 benzpyrene-induced rat fibrosarcoma HSN have been isolated and purified. Following cleavage from intact cells with trypsin, the peptides were purified by immunoaffinity chromatography and SDS-PAGE. Three polypeptides of molecular weight 120, 45 and 42 kDa were obtained that bound the specific rat monoclonal antibody (MAb) 11/160 in Western blots.
View Article and Find Full Text PDFRecent Results Cancer Res
January 1992
Institute of Cancer Research, Royal Cancer Hospital, Belmont, Surrey, Great Britain.
Carcinogenesis
June 1990
Chester Beatty Laboratories, Royal Cancer Hospital, London, UK.
Male and female CDF1 mice were administered a single oral dose of 3 mumol of the food mutagens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) or 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) and killed 24 h later. DNA was isolated from the livers, lungs, kidneys, colon and forestomach and analysed by 32P-postlabelling for the presence of IQ and MeIQ adducts. Several adduct-enrichment procedures were investigated, including ATP-deficient labelling conditions, butanol extraction and nuclease P1 digestion, and only the ATP-deficient procedure was found to produce the same adduct pattern on polyethyleneimine--cellulose TLC as the standard procedure.
View Article and Find Full Text PDFInt J Cancer
February 1990
Section of Medicine, Royal Cancer Hospital, Belmont, Sutton, Surrey, UK.
With the breast carcinoma cell line BT 474 used as a source of antigen, four rat monoclonal antibodies (MAbs) (3 IgG2a and I IgA) have been prepared against the external domain of the product of the c-erbB-2 proto-oncogene. All 4 antibodies stain frozen sections of tissues that over-express the product of the c-erbB-2 proto-oncogene, and competitive binding assays showed that the antibodies recognized 2 non-overlapping epitopes. Representative antibodies from the two groups (ICR12 and 13) were shown to specifically immunoprecipitate a 190 kDa protein from 35S-methionine-labelled breast carcinoma cells where the c-erbB-2 is amplified (BT 474 and MDA-MB 361).
View Article and Find Full Text PDFChem Biol Interact
May 1990
Chester Beatty Laboratories, Institute of Cancer Research, Royal Cancer Hospital, London, U.K.
3-Hydroxychrysene, a metabolite of the polycyclic aromatic hydrocarbon (PAH) chrysene, was metabolised by rat liver microsomal preparations obtained from Arochlor 1254-pretreated rats. Eight major metabolites were isolated by high performance liquid chromatography and characterised by u.v.
View Article and Find Full Text PDFChem Biol Interact
December 1990
Chester Beatty Laboratories, Institute of Cancer Research, Royal Cancer Hospital, London, U.K.
The effects of three aryl acetylenes, 1-ethynylpyrene (EP), 2-ethynylnaphthalene (EN) and 3-ethynylperylene (EPE), upon the metabolism of benzo[a]pyrene (BaP) by microsomes isolated from rat liver were investigated. These aryl acetylenes all inhibited the total metabolism of BaP. Formation of BaP 7,8-dihydrodiol and BaP tetrol products by microsomal preparations from rats that had been pretreated with 3-methylcholanthrene (3MC) were preferentially inhibited.
View Article and Find Full Text PDFImmunol Ser
July 1991
Institute of Cancer Research, Chester Beatty Laboratories, Royal Cancer Hospital, London, England.